SUZHOU, China, November 25, 2021, Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosing of first patient in Phase Ib Clinical Trial of MSB0254, a humanized anti-VEGFR-2 monoclonal antibody. MSB0254 has previously completed a Phase Ia clinical trial and established a Recommended Phase II Dose (RP2D).
The aim of the study is to evaluate the safety, tolerability, PK, and anti-tumor activity of MSB0254 at RP2D dose in multiple solid tumor types including neuroendocrine tumor, hepatocellular carcinoma and others.
MSB0254 is a high affinity humanized anti-VEGFR-2 mAb, with an anti-tumor mechanism of action by inhibiting tumor angiogenesis. MSB0254 has been generated using Transcenta’s in-house antibody discovery platform. Inhibition of angiogenic pathways has been well validated as an effective approach for the treatment of cancer and has shown promise in modulating immune microenvironment and enhancing the activities of immunotherapy. Transcenta will explore the potential of MSB0254 as a single agent or in combination with other compounds, including Transcenta pipeline molecules such as TST001 and TST005.